GOSS
Gossamer Bio, Inc.3.5600
-0.2300-6.07%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
823.98MP/E (TTM)
-Basic EPS (TTM)
-0.69Dividend Yield
0%Recent Filings
8-K
PROSERA misses primary, signals in subgroups
Gossamer Bio announced topline Phase 3 PROSERA results for inhaled seralutinib in PAH on February 23, 2026. It missed the primary 6MWD endpoint (+13.3m treatment effect, p=0.0320 vs α=0.025) due to high placebo response, yet shone in intermediate/high-risk patients (+20.0m) and CTD-APAH (+37.0m). Key secondaries favored seralutinib; well tolerated but with cough and liver elevations. Plans FDA talks; pauses SERANATA enrollment.
10-Q
Q3 FY2025 results
Gossamer Bio posted Q3 revenue of $13.3M from Chiesi collaboration, up 40% y/y yet down from YTD peaks after upfront license recognition. R&D expenses jumped 31% y/y to $45.5M on seralutinib trials, plus $7.5M IPR&D hit for Prana merger option via stock issuance; operating loss widened to $49.1M from $33.9M y/y, with net loss at $48.2M versus $30.8M as other income dipped. Cash burned $123M in operating activities YTD, leaving $180.2M in cash and marketable securities against $198M 5% 2027 Notes (fair value $142.5M). EPS reconciles at -$0.21 on 228M shares. Chiesi funds 100% of revenue. Clinical delays threaten cash runway.
8-K
Q3 loss widens; trials advance
Gossamer Bio reported Q3 net loss of $48.2M, up from $30.8M last year, as R&D expenses climbed to $45.5M amid Phase 3 progress. PROSERA PAH enrollment wrapped June; topline data due February 2026. First SERANATA PH-ILD site activated. Cash at $180M funds into 2027. Option to acquire Respira for 1.5M shares preserves liquidity.
8-K
Option to acquire Respira
Gossamer Bio secured an option to acquire Respira Therapeutics via merger with Prana, its parent, by issuing 2.5 million common shares on September 24, 2025. The option, exercisable until December 31, 2027 or key Respira milestones, includes up to 1.5 million more shares at close and ~6.7 million in contingent stock milestone payments. Equity issued unregistered under Section 4(a)(2). Deal hinges on regulatory and sales triggers.
8-K
Gossamer Q2 loss, trials advance
Gossamer Bio reported Q2 2025 financials, posting a $38.3 million net loss amid $41.6 million R&D spend, down from last year's profit due to absent one-time license revenue, while holding $212.9 million in cash to fund operations into 2027. The company completed enrollment in the Phase 3 PROSERA trial for seralutinib in PAH, eyeing topline data in February 2026, and plans first site activations for the PH-ILD SERANATA study this Q4. Cash runway supports the pivot to commercialization with Chiesi.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
GHRS
GH Research PLC
12.66+0.17
GLTO
Galecto, Inc.
30.00-1.60
GRI
GRI Bio, Inc.
0.48+0.00
GYRE
Gyre Therapeutics, Inc.
7.58+0.04
KROS
Keros Therapeutics, Inc.
21.53+0.30
PHAT
Phathom Pharmaceuticals, Inc.
15.24+0.55
PULM
Pulmatrix, Inc.
4.10-0.25
SVRA
Savara, Inc.
6.43-0.18
UPB
Upstream Bio, Inc.
29.32+2.12